pSivida Corp Announces Tech Evaluation Agreement for Tethadur™ Protein/Antibody Delivery System with Leading Biopharmaceutical Company

Published: Jul 30, 2012

WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that it has signed a funded technology evaluation agreement with a leading global biopharmaceutical company to evaluate pSivida’s Tethadur™ protein/antibody delivery technology in the field of ophthalmology.

Back to news